Department of Medicine, Hematology/Oncology Division, Feinberg School of Medicine, Chicago, IL 60611, USA.
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA.
Curr Oncol. 2024 Jul 14;31(7):4015-4021. doi: 10.3390/curroncol31070298.
A 48-year-old woman without obvious environmental risk factors was diagnosed with metastatic urothelial carcinoma harboring a mutation in typical of driver mutations for non-small cell lung cancer. Within a year, her cancer progressed on four standard therapies for urothelial cancer, including cancer in lungs, liver, bone, and brain. As fifth-line therapy, she received osimertinib, leading to a complete response in the brain and improvement elsewhere, and the cancer remained controlled for six months. Targeted therapy for rare driver mutations can be effective in urothelial cancer and should be considered prior to exhausting standard therapies.
一位 48 岁的女性，无明显环境风险因素，被诊断患有转移性尿路上皮癌，携带非小细胞肺癌驱动突变典型的突变。在一年内，她的癌症在四种标准的尿路上皮癌治疗方案中进展，包括肺部、肝脏、骨骼和脑部的癌症。作为第五线治疗，她接受了奥希替尼治疗，导致脑部完全缓解，其他部位也有所改善，癌症在六个月内得到控制。针对罕见驱动突变的靶向治疗在尿路上皮癌中可能有效，应在耗尽标准治疗方案之前考虑。
